The objectives of this contract are to conduct Phase 2 and early clinical trials of NCI-sponsored agents, to evaluate biologic effects of these agents on their molecular targets, to evaluate other relevant biologic effects and to determine clinically relevant outcomes/correlates. Major emphasis shall be on Phase 2 studies, pilot protocols that explore promising combination therapies, and high priority studies that are pivotal for drug development and require rapid initiation, completion, and data reporting. The NCI-IND agents to be studied shall include the following: a) Agents developed by the pharmaceutical industry and provided to the NCI for collaborative development;and agents developed by academic investigators and/or the Developmental Therapeutics Program (DTP), DCTD, NCI;b) Agents which have completed some or all Phase I testing, and: c) Combinations of agents for which the individual toxicities are known.

Agency
National Institute of Health (NIH)
Type
Research and Development Contracts (N01)
Project #
261201100039C-3-0-1
Application #
8740458
Study Section
Project Start
2011-09-23
Project End
2014-09-22
Budget Start
Budget End
Support Year
Fiscal Year
2013
Total Cost
$451,851
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030